AIM ImmunoTech's Ampligen Shows Synergistic Effect with Interferon-Alpha in Overcoming PD-1 Resistance in Cold Tumors
Key Insights
AIM ImmunoTech announced publication of a peer-reviewed study in the Journal for ImmunoTherapy of Cancer demonstrating positive combination effects of Ampligen and interferon-alpha on tumor growth and survival.
The research concluded that systemic chemokine modulation can eliminate PD-1 (search) resistance in cold tumors, suggesting intratumoral cytotoxic T-lymphocyte accumulation is the key limiting factor for immune checkpoint inhibitor effectiveness.
The findings indicate broad therapeutic potential for tumor microenvironment reprogramming strategies in cancer immunotherapy.
AIM ImmunoTech Inc. has announced the publication of new research demonstrating that its investigational drug Ampligen, when combined with interferon-alpha, shows positive effects on tumor growth and patient survival. The peer-reviewed study, published in the Journal for ImmunoTherapy of Cancer on September 18, provides evidence for overcoming resistance to PD-1 (search) checkpoint inhibitors in immunologically "cold" tumors.
Key Research Findings
The study, titled "Synergy between TLR3 (search)-ligand and IFN-α in the transient sensitization of 'Cold' tumors to PD-1 (search) blockade and the induction of systemic immunity," revealed that systemic chemokine modulation can eliminate PD-1 resistance in cold tumors. The research concluded that intratumoral cytotoxic T-lymphocyte accumulation, rather than tumor immunogenicity, represents the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors.
According to the published findings, the ability to modulate the tumor microenvironment through this combination approach suggests broad therapeutic potential for tumor microenvironment reprogramming strategies in cancer treatment.
Mechanism and Therapeutic Implications
Ampligen (rintatolimod) functions as a dsRNA and highly selective TLR3 (search) agonist immunomodulator. The research indicates that when combined with interferon-alpha, this approach can transiently sensitize cold tumors to PD-1 (search) blockade while inducing systemic immunity. Cold tumors, which typically show poor response to immunotherapy due to limited immune cell infiltration, represent a significant challenge in cancer treatment.
The study's findings suggest that the combination therapy works by enhancing the accumulation of cytotoxic T-lymphocytes within the tumor microenvironment, potentially transforming immunologically cold tumors into more responsive targets for checkpoint inhibitor therapy.
Clinical Development Context
AIM ImmunoTech describes itself as an immuno-pharma company focused on developing therapeutics for multiple types of cancers, immune disorders, and viral diseases, including COVID-19 (search). Ampligen represents the company's lead investigational product, currently in clinical trials for various cancer types, viral diseases, and immune system disorders.
The publication of this research in the Journal for ImmunoTherapy of Cancer adds to the growing body of evidence supporting combination approaches in cancer immunotherapy, particularly for addressing the challenge of checkpoint inhibitor resistance in certain tumor types.